Logo of arthrestherBioMed Centralbiomed central web sitesearchsubmit a manuscriptregisterthis articleArthritis Research & Therapy
Arthritis Res Ther. 2012; 14(1): R7.
Published online 2012 Jan 8. doi:  10.1186/ar3555
PMCID: PMC3392793

Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4



Osteoarthritis (OA) is a degenerative disease characterized by cartilage breakdown in the synovial joints. The presence of low-grade inflammation in OA joints is receiving increasing attention, with synovitis shown to be present even in the early stages of the disease. How the synovial inflammation arises is unclear, but proteins in the synovial fluid of affected joints could conceivably contribute. We therefore surveyed the proteins present in OA synovial fluid and assessed their immunostimulatory properties.


We used mass spectrometry to survey the proteins present in the synovial fluid of patients with knee OA. We used a multiplex bead-based immunoassay to measure levels of inflammatory cytokines in serum and synovial fluid from patients with knee OA and from patients with rheumatoid arthritis (RA), as well as in sera from healthy individuals. Significant differences in cytokine levels between groups were determined by significance analysis of microarrays, and relations were determined by unsupervised hierarchic clustering. To assess the immunostimulatory properties of a subset of the identified proteins, we tested the proteins' ability to induce the production of inflammatory cytokines by macrophages. For proteins found to be stimulatory, the macrophage stimulation assays were repeated by using Toll-like receptor 4 (TLR4)-deficient macrophages.


We identified 108 proteins in OA synovial fluid, including plasma proteins, serine protease inhibitors, proteins indicative of cartilage turnover, and proteins involved in inflammation and immunity. Multiplex cytokine analysis revealed that levels of several inflammatory cytokines were significantly higher in OA sera than in normal sera, and levels of inflammatory cytokines in synovial fluid and serum were, as expected, higher in RA samples than in OA samples. As much as 36% of the proteins identified in OA synovial fluid were plasma proteins. Testing a subset of these plasma proteins in macrophage stimulation assays, we found that Gc-globulin, α1-microglobulin, and α2-macroglobulin can signal via TLR4 to induce macrophage production of inflammatory cytokines implicated in OA.


Our findings suggest that plasma proteins present in OA synovial fluid, whether through exudation from plasma or production by synovial tissues, could contribute to low-grade inflammation in OA by functioning as so-called damage-associated molecular patterns in the synovial joint.


Osteoarthritis (OA) is a degenerative disease of the joints that is characterized by destruction of articular cartilage, inflammation of the synovial membrane (synovitis), and remodeling of periarticular bone. Which of these pathogenic processes occurs first is unknown. One proposed scenario is that cartilage breakdown (due to injury or mechanical stress) releases components of the damaged extracellular matrix (ECM) into synovial fluid, and that these ECM components elicit the local production of inflammatory molecules by binding to receptors on resident synovial cells or infiltrating inflammatory cells [1,2]. The inflammatory molecules produced may in turn stimulate production of cartilage-degrading enzymes and recruit inflammatory cells to the affected joint [3,4], thus establishing a vicious cycle of cartilage destruction and inflammation that perpetuates and promotes the OA pathology. Therefore, OA has been described as a chronic wound in which molecules in synovial fluid function as damage-associated molecular patterns (DAMPs; that is, endogenous molecules produced during injury that signal through inflammatory toll-like receptors (TLRs) to effect tissue remodeling) [2,5,6]. Although the identities of the endogenous molecules that mediate synovial inflammation have yet to be confirmed in OA patients or animal models, a continuous supply of DAMPs could perpetuate the early response to injury and thereby damage the joint.

Besides ECM components, many other molecules may act as DAMPs [2]. One such molecule is fibrinogen, which stimulates macrophage production of chemokines in a TLR4-dependent manner [7-9]. Fibrinogen is present at abnormally high levels in OA synovial fluid [10], and the amount of fibrin (the thrombin-cleaved form of fibrinogen [11]) deposited in the synovial membrane correlates with the severity of OA [12]. Although classically a plasma protein, fibrinogen exudes from the vasculature at sites of inflammation, such as the inflamed OA joint, owing to the retraction of inflamed endothelial cells [11]. Fibrinogen is not the only protein to extravasate at sites of inflammation, however, and several other plasma proteins have been detected in OA synovial fluid [10,13]. The extravascular function of most of these plasma proteins is unclear. It is possible that, like fibrinogen, some of these plasma proteins could have an immunoregulatory role at sites of inflammation or tissue damage.

Inflammation is present even in the early stages of OA [14,15], and clinical signs of synovitis correlate with radiographic progression of knee OA [16]. Insight into the cause of synovial inflammation is therefore important in understanding the pathogenesis of OA. Here we used proteomic techniques to survey the proteins present in OA synovial fluid and to evaluate levels of inflammatory cytokines in OA serum and synovial fluid. We then determined whether a subset of the identified proteins could promote inflammation by functioning as immunostimulatory DAMPs.

Material and methods

Synovial fluid and serum samples

Serum and synovial fluid samples were obtained from patients with knee OA, patients with rheumatoid arthritis (RA), or healthy individuals under protocols approved by the Stanford University Institutional Review Board and with the patients' informed consent. Synovial fluid aspiration was performed by a board-certified rheumatologist by fine-needle arthrotomy, and the synovial fluid samples obtained were free from obvious contamination with blood or debris. OA serum and synovial fluid samples were obtained from patients diagnosed with knee OA (of Kellgren-Lawrence score 2 to 4 [17]) according to the 1985 criteria of the American Rheumatism Association [18]. For mass spectrometric analysis, OA synovial fluid samples were from five Caucasian men aged 50 to 75 years who met the 1985 OA criteria [18]; exclusion criteria included radiographic evidence of chondrocalcinosis or evidence of crystals under polarizing microscopy. Demographics and clinical characteristics of these five individuals are shown in Table Table1.1. Synovial fluids from the other OA patients and from the RA patients were provided as de-identified remnant clinical samples, and patient demographics were therefore unavailable for these samples. All RA patients met the 1987 American Rheumatism Association criteria for RA [19] and had RA of less than 6 months' duration; exclusion criteria included concurrent infectious or crystal arthritis. Samples of "normal" serum were obtained from healthy individuals who had no joint pain and no radiographic evidence of knee arthritis [20]. OA and normal sera were matched by age, sex, and BMI. Serum and synovial fluid samples were not matched but were derived from patients with the characteristics described earlier. All samples were aliquoted and stored at -80°C.

Table 1
Clinical and demographic characteristics of OA patients whose synovial fluid was analyzed with mass spectrometry

Mass spectrometric analysis

Synovial fluid proteins were separated by 1D or 2D polyacrylamide gel electrophoresis (PAGE), trypsinized, and identified by liquid chromatography tandem mass spectrometry (LCMS), as follows. Fifty microliters of frozen synovial fluid was diluted to a final volume of 1 ml in phosphate buffered saline (PBS) containing Halt protease and phosphatase inhibitor (Thermo Fisher Scientific), and then depleted of the highly abundant proteins albumin and immunoglobulin G (IgG) by using the ProteoPrep Immunoaffinity Albumin & IgG Depletion Kit (Sigma-Aldrich) according to the manufacturer's instructions. In brief, synovial fluids were twice passed over spin columns prepacked with a mixture of two beaded mediums containing recombinantly expressed, small, single-chain antibody ligands. The flow-through fractions containing synovial fluid depleted of albumin and IgG were diluted 1:1 with Laemmli Sample Buffer (BioRad) and then subjected to 1D-PAGE or 2D-PAGE analysis. Because a small number of proteins other than albumin and IgG may bind to the medium in the spin columns, the bound proteins were eluted with Laemmli sample buffer and also subjected to PAGE analysis. For 1D-PAGE analysis, proteins were boiled for 10 minutes and separated on Precast Criterion XCT gels (4% to 12% linear gradient, BioRad). After electrophoresis, the gels were stained for 1 hour with Gelcode blue (Pierce) and destained overnight. For 2D-PAGE analysis, methods were as previously described [21]. In brief, 100 μg of synovial fluid proteins was dissolved in 150 μl of isoelectric focusing (IEF) buffer (ReadyPrep Sequential Extraction Kit Reagent 3, BioRad). For the first-dimension electrophoresis, 150 μl (at a 1 μg/μl concentration) of sample solution was applied to an 11-cm Ready-Strip Immobilized pH Gradient (IPG) strip, pH 3 to 10 (BioRad). The IPG strips were soaked in the sample solution for 1 hour, to allow uptake of the proteins, and then actively rehydrated in the Protean IEF cell (BioRad) for 12 hours at 50 V. IEF was performed for 1 hour at each of 100, 200, 500, and 1,000 V, and then for 10 hours at 8,000 V. For second-dimension electrophoresis, IPG strips were equilibrated for 20 minutes in 50 mM Tris-HCl, pH 8.8, containing 6 M urea, 1%SDS, 30% glycerol, and 65 mM dithiothreitol (DTT), and then re-equilibrated for 20 minutes in the same buffer containing 260 mM iodacetamide in place of DTT. Precast Criterion XCT gels (4% to 12% linear gradient, BioRad) were used for the second-dimension electrophoresis, as was done for the 1D-PAGE. After electrophoresis, the gels were stained for 1 hour with Gelcode blue (Pierce) and destained overnight.

The stained protein bands and spots (from the 1D-PAGE and 2D-PAGE, respectively) were cut out of the gels, immersed in 10 mM ammonium bicarbonate containing 10 mM DTT and 100 mM iodoacetamide, treated with 100% acetonitrile, and then digested overnight at 37°C with 0.1 mg trypsin (Sigma-Aldrich) in 10 mM ammonium acetate containing 10% acetonitrile. The trypsinized proteins were identified with LCMS by using the Agilent 1100 LC system and the Agilent XCT Ultra Ion Trap (Agilent Technologies, Santa Clara, CA) as previously described [22]. We scanned the LCMS data against the SwissProt database by using the SpectrumMill software (Agilent). We required the detection of at least two peptides for identification of a protein, and a significance level of P ≤ 0.05 for identification of each peptide. The significance level of peptide identification takes into account the number of ionization forms of the fragmented peptide that match with a particular protein in the SwissProt database (with penalties for ionization forms not identified), as well as the total intensity of each ionization form [23].

Multiplex cytokine analysis

Multiplex analysis of cytokines and chemokines in human serum and synovial fluid samples was performed by using both the 27-plex and the 21-plex Bio-Plex Pro Human Cytokine Assay (BioRad) run on the Luminex 200 platform, as recommended by the manufacturers. Performing the Bio-Plex assay with the kit reagents, we found that several commercial reagents designed to block the confounding effect of heterophilic antibodies, including ones we used previously with other cytokine assay kits [24], did not significantly affect the readout of the Bio-Plex assay; we therefore did not use such blocking reagents with the Bio-Plex assay. Data processing was performed by using Bio-Plex Manager 5.0, and analyte concentrations (in picograms per milliliter) were interpolated from standard curves. Statistical differences in cytokine levels were calculated with significance analysis of microarrays (SAM [25]), and the SAM-generated results with a false discovery rate (FDR) of less than 10% were selected. To identify relations and to display our results most effectively, we normalized the analyte concentrations as follows: all values less than 1 were designated as 1, and the mean concentration of each analyte in the "normal serum" samples was calculated; the analyte value in the sample was then divided by the mean analyte value in normal serum, and finally, a log-base-2 transformation was applied. Results were subjected to unsupervised hierarchic clustering by using Cluster 3.0, which arranges the SAM-generated results according to similarities in cytokine levels, and the clustering results were displayed by using Java Treeview (Version 1.1.3).

Macrophage stimulation assays

To generate mouse macrophages, we differentiated bone-marrow cells isolated from wild-type C57BL/6 mice and from B6.B10ScN-Tlr4lps-del mice (Jackson Laboratory) according to standard procedures [26]. In brief, the femur and tibia were flushed with α-minimal essential medium (MEM; Invitrogen) by using a 1-ml syringe and a 25-gauge needle. The resulting cell suspension was lysed with ACK Lysing Buffer (Invitrogen) for removal of erythrocytes. Cell clumps were removed by filtering through a 70-μm cell strainer (BD). The remaining cells in the suspension were cultured on 100-mm culture dishes in α-MEM supplemented with 10% fetal bovine serum (FBS), 100 units/ml of penicillin, 100 μg/ml of streptomycin, and 2 mM glutamine (Invitrogen) for 16 to 24 hours in 5% CO2 at 37°C. Nonadherent cells were collected, plated on 100-mm dishes, and differentiated into bone-marrow-derived macrophages (BMMs) for 6 days in the presence of 30 ng/ml of macrophage colony-stimulating factor (PeproTech). To generate human monocyte-derived macrophages (MDMs), we collected peripheral blood mononuclear cells (PBMCs) by performing density-gradient centrifugation of LRS chamber content (Stanford Blood Center) over Ficoll (Invitrogen), purified human monocytes by negative selection by using a monocyte isolation kit (Miltenyi Biotec), and differentiated the monocytes into macrophages by culturing them for 7 days in RPMI containing 10% FBS and 30 ng/ml of human M-CSF.

For stimulation assays, mouse BMMs were plated in 96-well plates at 1 × 105 cells/well, and human macrophages at 7 × 104 cells/well. Cells were incubated for 24 hours with lipopolysaccharide (LPS; Sigma-Aldrich), peptidoglycan (InvivoGen), α1-microglobulin (Cell Sciences), α2-macroglobulin (EMD Chemicals), α1-acid glycoprotein (EMD Chemicals), Gc-globulin (also known as vitamin D-binding protein; Abcam), haptoglobin (Sigma-Aldrich), or human serum albumin (Sigma-Aldrich). We measured levels of interleukin-1β (IL-1β), interleukin-6 (IL-6), and vascular endothelial growth factor (VEGF) in the culture supernatants with Luminex analysis, by using a 27-plex Bio-Plex Pro Human Cytokine Assay kit (BioRad) according to the manufacturer's instructions. We measured TNF levels with enzyme-linked immunosorbent assay (ELISA; PeproTech). For the TNF ELISA, the limits of detection were 16 to 2,000 pg/ml for mouse TNF, and 23 to 1,500 pg/ml for human TNF. For the Luminex assay, the limits of detection were 3.2 to 3,261 pg/ml for IL-1β, 2.3 to 18,880 pg/ml for IL-6, and 5.5 to 56,237 pg/ml for VEGF. To exclude a contribution of endotoxin contamination, we included 10 μg/ml of polymyxin B (Sigma-Aldrich) in some of the stimulation assays. As an additional control for endotoxin contamination, we tested whether preincubating the plasma proteins with proteinase K and β-mercaptoethanol at 55°C for 4 hours (and then at 100°C for 10 minutes to inactivate the proteinase K) abrogated their ability to induce the production of cytokines (the plasma proteins, but not any contaminating endotoxin, would be denatured under these conditions).

Statistical analysis

One-way ANOVA and unpaired t test (Graph-Pad Software) were used to analyze differences in levels of cytokines. P values less than 0.05 were considered significant.

Results and Discussion

We first used mass spectrometry to survey the proteins present in the synovial fluid of patients with knee OA. Synovial fluid proteins from five OA patients were separated by 1D- or 2D-PAGE and then identified by LCMS. Analysis of all five samples identified a total of 111 unique proteins; three of these were keratin proteins, skin proteins most likely obtained as a result of the cutaneous puncture performed during aspiration of the synovial joints. Eliminating these keratins left 108 unique proteins (Tables (Tables22 and and3),3), most of which were detected in all synovial fluid samples analyzed. Of these, 44 were identified in a previous proteomic survey of highly abundant proteins in OA synovial fluid [10] (Table (Table2).2). Thus, we confirmed the presence of serine protease inhibitors (for example, antithrombin III, α1-antitrypsin, α1-antichymotrypsin, kininogen 1) and of proteins important in regulating proteases that degrade cartilage ECM. We also confirmed the presence of proteins involved in cartilage (for example, fibronectin) and/or collagen (for example, gelsolin and collagen α1, α2, and α3 chains) metabolism, and of proteins involved in inflammation or immunity (for example, fibrinogen, AGP 1, complement factors, immunoglobulins, cytokines) (Table (Table2),2), findings consistent with the inflammation, ECM degradation, and immune-cell infiltration that characterize OA. Among the 64 proteins that we newly identified (Table (Table3)3) were histone-related proteins, macrophage-related proteins, proinflammatory receptors, and proteins related to the proinflammatory transcription factor nuclear factor kappa B (Table (Table4),4), presumably reflecting the turnover of resident synovial cells or infiltrating inflammatory cells.

Table 2
Proteins identified in OA synovial fluids in this study and in a previous proteomic study [10]
Table 3
Proteins newly identified in OA synovial fluids
Table 4
Classes of proteins newly identified in OA synovial fluids

Our mass-spectrometric findings revealed the presence of many molecules associated with inflammation. Although cytokines are also classically associated with inflammation, PAGE-based mass spectrometry is not well suited to the detection of small proteins such as cytokines. We therefore used a multiplex immunoassay to measure levels of inflammatory cytokines and chemokines in synovial fluid samples from 12 patients with knee OA and 14 patients with RA, as well as in serum samples from 24 patients with knee OA, 23 patients with RA, and 35 healthy individuals. Samples from patients with RA, a classic inflammatory arthritis, were used as a comparator. Figure Figure11 shows a heatmap of the relative levels of cytokines in the five groups of samples. Compared with cytokine levels in normal sera, cytokine levels in OA sera were generally slightly higher, and those in RA sera were much higher (Figure (Figure1).1). SAM analysis revealed that levels of several inflammatory cytokines (for example, IL-1β and IL-6), chemokines (for example, IP-10 (also known as CXCL10), MCP-1, IL-8, MIG, and MIP-1β), and growth factors (for example, VEGF and SCGF-β) were significantly higher in OA sera than in normal sera (FDR < 10%; Figure Figure2),2), consistent with previous reports of the association of OA with such inflammatory mediators [27]. Interestingly, we also found OA-associated elevations in levels of IL-9 and cutaneous T-cell attracting chemokine (CTACK), supporting the concept that T cells play a role in OA [28]. As expected, cytokine levels were significantly higher in RA sera than in OA sera (Figure (Figure3;3; FDR < 10%).

Figure 1
Inflammatory cytokines are associated with osteoarthritis. Relative cytokine levels in serum and synovial fluid (SF) samples from patients with osteoarthritis (OA) or rheumatoid arthritis (RA) and in serum samples from healthy individuals (normal sera). ...
Figure 2
Levels of inflammatory cytokines are higher in OA compared with healthy sera. Cytokines whose levels differ significantly between sera from individuals with osteoarthritis (OA) and sera from age-matched healthy individuals (FDR < 10%). Significance ...
Figure 3
Levels of inflammatory cytokines are higher in RA compared with OA sera. Cytokines whose levels differ significantly between sera from individuals with osteoarthritis (OA) and sera from individuals with rheumatoid arthritis (RA) (FDR < 10%). Significance ...

Unlike RA, OA is considered a disorder that is restricted to the joints. Indeed, levels of multiple cytokines were much higher in OA synovial fluids than in OA sera (Figure (Figure11 and Table Table5);5); levels of TNF were negligible in OA sera but substantial in OA synovial fluid (Figure (Figure11 and Table Table5).5). Our findings suggest that the abnormally high levels of cytokines in OA sera largely reflect overproduction of these cytokines in the joint, consistent with the finding that levels of high-sensitivity C-reactive protein in the serum of OA patients correlate with the degree of inflammatory infiltrate in the patients' joints [29]. Thus, OA is associated with low-grade inflammation that may originate in the joints.

Table 5
Absolute and relative cytokine levels in healthy and OA serum, and in OA synovial fluid

Interestingly, 39 (36%) of the proteins we identified in OA synovial fluid are classically considered plasma proteins (Tables (Tables22 and and3).3). Indeed, plasma proteins form a large proportion of the proteins enriched in OA synovial fluid relative to healthy synovial fluid [10]. What might these plasma proteins be doing in the OA joint? Like certain products of ECM breakdown [2,5,6], the plasma protein fibrinogen can function as a DAMP and has been proposed to contribute to the pathogenesis of inflammatory arthritis [7-9]. We therefore examined whether other plasma proteins in OA synovial fluid can function as immunostimulatory DAMPs that could contribute to the low-grade inflammation associated with OA.

Key players in OA-associated inflammation are the macrophages [27,30,31]. The cell infiltrate in human OA joints consists mainly of macrophages, and mice depleted of macrophages are relatively resistant to collagenase-induced OA [30]. Macrophages from OA joints produce a number of growth factors, such as VEGF, and inflammatory cytokines, such as the major OA-associated cytokines IL-1β and TNF [30]. We detected VEGF, IL-1β, and TNF in OA synovial fluid in our cytokine screen (Figure (Figure11 and Table Table5)5) and found that levels of VEGF and IL-1β are significantly higher in OA sera than in normal sera (Figure (Figure2).2). VEGF may promote OA pathology by inducing angiogenesis (and thereby osteophyte formation) and by inducing matrix metalloprotease production (and thereby cartilage degradation) [32]. The cytokines produced by macrophages amplify the inflammation in the joints by inducing synovial cells to produce further cytokines and chemokines, as well as matrix metalloproteases [30]. Moreover, macrophages express many of the receptors that mediate DAMP signaling, and they can thus trigger an inflammatory cascade in response to DAMPs present in OA synovial fluid [7-9].

We therefore assessed whether a subset of the identified plasma proteins could induce macrophages to produce TNF, a key cytokine that is thought to drive the inflammatory cascade in OA [27]. We tested α1-microglobulin (α1m), α1-acid glycoprotein 1 (AGP 1; also known as orosomucoid 1), α2-macroglobulin (α2m), Gc-globulin (also known as vitamin D-binding protein), albumin, and haptoglobin, all of them plasma proteins detected in our survey of synovial fluid proteins (Table (Table2)2) and shown to be enriched in OA synovial fluid [10]. With mouse macrophages, we found that α1m, α2m, and Gc-globulin, at concentrations similar to those measured in synovial fluid [33-35], each dose-dependently stimulated the production of TNF, whereas AGP 1, albumin, and haptoglobin did not (Figure (Figure4a).4a). The plasma proteins ceruloplasmin, complement component C3, complement component C4, β2-glycoprotein (also known as apolipoprotein H) also did not stimulate TNF production (data not shown).

Figure 4
Plasma proteins detected in osteoarthritic synovial fluid are immunostimulatory. Mouse bone-marrow-derived macrophages (BMMs) and human monocyte-derived macrophages (MDMs) were stimulated for 24 hours with plasma proteins detected in osteoarthritic synovial ...

We next examined the effect of α1m, α2m, and Gc-globulin on cytokine production in human macrophages. Because the endotoxin LPS is a common contaminant and is itself an agonist of TLR4, we tested the stimulatory properties of the plasma proteins in the presence of polymyxin B, a compound that neutralizes LPS. In the presence of polymyxin B, α1m-, α2m-, and Gc-globulin-induced TNF production was not significantly reduced, whereas LPS-induced TNF production was abrogated (Figure (Figure4b).4b). Additionally, pretreatment with proteinase K significantly abrogated TNF production induced by the plasma proteins but not TNF production induced by LPS (Figure (Figure5).5). Although we cannot exclude the possibility that a small component of the observed stimulation is due to endotoxin, this result confirms that the plasma proteins are themselves immunostimulatory. Gc-globulin, α1m, and α2m were also able to induce the production of several other inflammatory cytokines that were upregulated in OA serum and synovial fluid (Figures (Figures11 and and2):2): IL-1β, IL-6, and VEGF (Figure (Figure4c).4c). Thus, Gc-globulin, α1m, and α2m can each induce the production of TNF, IL-1β, IL-6, and VEGF, all molecules implicated in the pathogenesis of OA [27,30,31].

Figure 5
Induction of TNF production by plasma proteins is not due to endotoxin contamination. RAW264.7 macrophages were stimulated for 24 hours with 50 μg/ml of Gc-globulin, α1-microglobulin (α1m), or α2-macroglobulin (α ...

But how do these plasma proteins stimulate cytokine production? To determine whether these immunostimulatory plasma proteins signal through TLR4, we examined whether Gc-globulin, α1m, and α2m could also induce TNF production in TLR4-deficient macrophages. TLR4 deficiency inhibited Gc-globulin-, α1m-, and α2m-induced TNF production (Figure (Figure6).6). Confirming that the defect in inflammatory signaling in the Tlr4lps-del macrophages was specific to the TLR4 pathway, theTLR2-specific agonist peptidoglycan was able to induce TNF production in these cells-in fact, to a greater degree than in wild-type cells (possibly because of compensatory mechanisms operating within the TLR family) (Figure (Figure6).6). Thus, Gc-globulin-, α1m-, and α2m-induced production of TNF is dependent on TLR4.

Figure 6
Plasma proteins detected in osteoarthritic synovial fluid stimulate macrophage TNF production via TLR4. Levels of TNF produced by wild-type (wt) or TLR4-deficient (Tlr4lps-del) mouse bone-marrow-derived macrophages stimulated for 24 hours with 50 μg/ml ...

Interest in the putative immunomodulatory effects of α1m, α2m, and Gc-globulin is increasing, with both proinflammatory and antiinflammatory properties suggested for each of them [36-38].

For example, α1m has been shown to bind to the surface of various inflammatory cells and to either stimulate or inhibit the activation of human lymphocytes [38]. The immunoregulatory role of α1m in health and disease is likely to be context dependent. Gc-globulin, however, appears to be primarily proinflammatory: it enhances the neutrophil- and monocyte-chemotactic activity of the anaphylatoxin C5a [36] and, in its sialic-acid-free form, activates macrophages [39]. Here, we uncover an additional mechanism by which these plasma proteins could promote inflammation. We speculate that exudation into extravascular spaces at sites of tissue damage and inflammation may render these plasma proteins inflammatory by bringing them into contact with TLR-expressing macrophages. Our finding that certain plasma proteins present in OA synovial fluid can induce macrophage production of inflammatory cytokines supports the model of local production of inflammatory mediators in the joints in OA.


We identified 108 proteins in OA synovial fluid and showed that OA is associated with low-grade inflammation. We found that plasma proteins form a large proportion of the proteins present in OA synovial fluid and that certain of these plasma proteins can signal through TLR4 to induce the production of an array of inflammatory cytokines, including those upregulated in OA. Our findings suggest that plasma proteins present in OA synovial fluid, whether through exudation from the plasma or production by synovial tissues, could contribute to low-grade inflammation in OA by functioning as DAMPs.


α1m: α1-microglobulin; AGP 1: α1-acid glycoprotein 1; α2m: α2-macroglobulin; BMM: bone-marrow-derived macrophage; DAMP: damage-associated molecular pattern; ECM: extracellular matrix; IL-1β: interleukin-1β; IL-6: interleukin-6; IP-10: interferon gamma-induced protein 10; LCMS: chromatography tandem mass spectrometry; LPS: lipopolysaccharide; MCP-1: macrophage chemotactic protein-1; MDM: monocyte-derived macrophage; MEM: minimal essential medium; MIG: monokine induced by interferon-γ; MIP-1: macrophage inflammatory protein-1; OA: osteoarthritis; PAGE: polyacrylamide gel electrophoresis; RA: rheumatoid arthritis; TLR: Toll-like receptor; TNF: tumor necrosis factor; VEGF: vascular endothelial growth factor.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

JS and WHR conceived the studies. OS performed the mass spectrometric analysis of synovial fluid. PEC, LJL, and JCE performed the multiplex cytokine analysis. JCE, KAB, and TPA collected and provided OA sera. DHS performed the in vitro macrophage stimulation assays. JS, WHR, DHS, OS, TML, and IH analyzed the resulting datasets. TML and JS wrote and edited the manuscript with the input of WHR, OS, and DHS. All authors read and approved the final manuscript.


See related editorial by Goldring and Scanzello, http://arthritis-research.com/content/14/2/111


This study was funded by VA RR&D Merit Review Award and N01-HV-00242 NHLBI Proteomics Center funding to WHR.


  • Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol. 2010;6:625–35. doi: 10.1038/nrrheum.2010.159. [PubMed] [Cross Ref]
  • Scanzello CR, Plaas A, Crow MK. Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound? Curr Opin Rheumatol. 2008;20:565–72. doi: 10.1097/BOR.0b013e32830aba34. [PubMed] [Cross Ref]
  • Bondeson J, Wainwright SD, Lauder S, Amos N, Hughes CE. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther. 2006;8:R187. doi: 10.1186/ar2099. [PMC free article] [PubMed] [Cross Ref]
  • Woodell-May J, Matuska A, Oyster M, Welch Z, O'Shaughnessey K, Hoeppner J. Autologous protein solution inhibits MMP-13 production by IL-1beta and TNFalpha-stimulated human articular chondrocytes. J Orthop Res. 2011;29:1320–6. doi: 10.1002/jor.21384. [PubMed] [Cross Ref]
  • Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, Drexler S, Sofat N, Kashiwagi M, Orend G, Brennan F, Foxwell B. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med. 2009;15:774–80. doi: 10.1038/nm.1987. [PubMed] [Cross Ref]
  • Sofat N. Analysing the role of endogenous matrix molecules in the development of osteoarthritis. Int J Exp Pathol. 2009;90:463–79. doi: 10.1111/j.1365-2613.2009.00676.x. [PMC free article] [PubMed] [Cross Ref]
  • Kuhns DB, Priel DA, Gallin JI. Induction of human monocyte interleukin (IL)-8 by fibrinogen through the Toll-like receptor pathway. Inflammation. 2007;30:178–88. doi: 10.1007/s10753-007-9035-1. [PubMed] [Cross Ref]
  • Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J Immunol. 2001;167:2887–94. [PubMed]
  • Sokolove J, Zhao X, Chandra PE, Robinson WH. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor. Arthritis Rheum. 2011;63:53–62. [PMC free article] [PubMed]
  • Gobezie R, Kho A, Krastins B, Sarracino DA, Thornhill TS, Chase M, Millett PJ, Lee DM. High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Res Ther. 2007;9:R36. doi: 10.1186/ar2172. [PMC free article] [PubMed] [Cross Ref]
  • Furie B, Furie BC. The molecular basis of blood coagulation. Cell. 1988;53:505–18. [PubMed]
  • Loeuille D, Chary-Valckenaere I, Champigneulle J, Rat AC, Toussaint F, Pinzano-Watrin A, Goebel JC, Mainard D, Blum A, Pourel J, Netter P, Gillet P. Macroscopic and microscopic features of synovial membrane inflammation in the osteoarthritic knee: correlating magnetic resonance imaging findings with disease severity. Arthritis Rheum. 2005;52:3492–501. doi: 10.1002/art.21373. [PubMed] [Cross Ref]
  • Pruzanski W, Russell ML, Gordon DA, Ogryzlo MA. Serum and synovial fluid proteins in rheumatoid arthritis and degenerative joint diseases. Am J Med Sci. 1973;265:483–90. doi: 10.1097/00000441-197306000-00007. [PubMed] [Cross Ref]
  • Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis. 2005;64:1263–7. doi: 10.1136/ard.2004.025270. [PMC free article] [PubMed] [Cross Ref]
  • Felson DT. Clinical practice: osteoarthritis of the knee. N Engl J Med. 2006;354:841–8. doi: 10.1056/NEJMcp051726. [PubMed] [Cross Ref]
  • Ledingham J, Regan M, Jones A, Doherty M. Factors affecting radiographic progression of knee osteoarthritis. Ann Rheum Dis. 1995;54:53–8. doi: 10.1136/ard.54.1.53. [PMC free article] [PubMed] [Cross Ref]
  • Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16:494–502. doi: 10.1136/ard.16.4.494. [PMC free article] [PubMed] [Cross Ref]
  • Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, Howell D, Kaplan D, Koopman W, Longley S III, Mankin H, McShane DJ, Medsger T Jr, Meenan R, Mikkelsen W, Moskowitz R, Murphy W, Rothschild B, Segal M, Sokoloff L, Wolfe F. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee; Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29:1039–49. doi: 10.1002/art.1780290816. [PubMed] [Cross Ref]
  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24. doi: 10.1002/art.1780310302. [PubMed] [Cross Ref]
  • Mundermann A, King KB, Smith RL, Andriacchi TP. Change in serum COMP concentration due to ambulatory load is not related to knee OA status. J Orthop Res. 2009;27:1408–13. doi: 10.1002/jor.20908. [PubMed] [Cross Ref]
  • Elchuri S, Naeemuddin M, Sharpe O, Robinson WH, Huang TT. Identification of biomarkers associated with the development of hepatocellular carcinoma in CuZn superoxide dismutase deficient mice. Proteomics. 2007;7:2121–9. doi: 10.1002/pmic.200601011. [PMC free article] [PubMed] [Cross Ref]
  • Lopez-Avila V, Sharpe O, Robinson WH. Determination of ceruloplasmin in human serum by SEC-ICPMS. Anal Bioanal Chem. 2006;386:180–7. doi: 10.1007/s00216-006-0528-9. [PubMed] [Cross Ref]
  • Kapp EA, Schutz F, Reid GE, Eddes JS, Moritz RL, O'Hair RA, Speed TP, Simpson RJ. Mining a tandem mass spectrometry database to determine the trends and global factors influencing peptide fragmentation. Anal Chem. 2003;75:6251–64. doi: 10.1021/ac034616t. [PubMed] [Cross Ref]
  • Hueber W, Tomooka BH, Zhao X, Kidd BA, Drijfhout JW, Fries JF, van Venrooij WJ, Metzger AL, Genovese MC, Robinson WH. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with upregulation of proinflammatory cytokines. Ann Rheum Dis. 2007;66:712–9. doi: 10.1136/ard.2006.054924. [PMC free article] [PubMed] [Cross Ref]
  • Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA. 2002;99:6567–72. doi: 10.1073/pnas.082099299. [PMC free article] [PubMed] [Cross Ref]
  • Stanley ER. Murine bone marrow-derived macrophages. Methods Mol Biol. 1997;75:301–4. [PubMed]
  • Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7:33–42. doi: 10.1038/nrrheum.2010.196. [PubMed] [Cross Ref]
  • Sakkas LI, Platsoucas CD. The role of T cells in the pathogenesis of osteoarthritis. Arthritis Rheum. 2007;56:409–24. doi: 10.1002/art.22369. [PubMed] [Cross Ref]
  • Pearle AD, Scanzello CR, George S, Mandl LA, DiCarlo EF, Peterson M, Sculco TP, Crow MK. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage. 2007;15:516–23. doi: 10.1016/j.joca.2006.10.010. [PubMed] [Cross Ref]
  • Bondeson J, Blom AB, Wainwright S, Hughes C, Caterson B, van den Berg WB. The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum. 2010;62:647–57. [PubMed]
  • Farahat MN, Yanni G, Poston R, Panayi GS. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 1993;52:870–5. doi: 10.1136/ard.52.12.870. [PMC free article] [PubMed] [Cross Ref]
  • Murata M, Yudoh K, Masuko K. The potential role of vascular endothelial growth factor (VEGF) in cartilage: how the angiogenic factor could be involved in the pathogenesis of osteoarthritis. Osteoarthritis Cartilage. 2008;16:279–86. doi: 10.1016/j.joca.2007.09.003. [PubMed] [Cross Ref]
  • Cawston TE, McLaughlin P, Hazleman BL. Paired serum and synovial fluid values of alpha 2-macroglobulin and TIMP in rheumatoid arthritis. Br J Rheumatol. 1987;26:354–8. doi: 10.1093/rheumatology/26.5.354. [PubMed] [Cross Ref]
  • Fairney A, Straffen AM, May C, Seifert MH. Vitamin D metabolites in synovial fluid. Ann Rheum Dis. 1987;46:370–4. doi: 10.1136/ard.46.5.370. [PMC free article] [PubMed] [Cross Ref]
  • Takagi K, Kin K, Itoh Y, Enomoto H, Kawai T. Human alpha 1-microglobulin levels in various body fluids. J Clin Pathol. 1980;33:786–91. doi: 10.1136/jcp.33.8.786. [PMC free article] [PubMed] [Cross Ref]
  • Kew RR, Webster RO. Gc-globulin (vitamin D-binding protein) enhances the neutrophil chemotactic activity of C5a and C5a des Arg. J Clin Invest. 1988;82:364–9. doi: 10.1172/JCI113596. [PMC free article] [PubMed] [Cross Ref]
  • Logdberg L, Wester L. Immunocalins: a lipocalin subfamily that modulates immune and inflammatory responses. Biochim Biophys Acta. 2000;1482:284–97. doi: 10.1016/S0167-4838(00)00164-3. [PubMed] [Cross Ref]
  • Akerstrom B, Logdberg L, Berggard T, Osmark P, Lindqvist A. alpha(1)-Microglobulin: a yellow-brown lipocalin. Biochim Biophys Acta. 2000;1482:172–84. doi: 10.1016/S0167-4838(00)00157-6. [PubMed] [Cross Ref]
  • Yamamoto N, Homma S. Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA. 1991;88:8539–43. doi: 10.1073/pnas.88.19.8539. [PMC free article] [PubMed] [Cross Ref]

Articles from Arthritis Research & Therapy are provided here courtesy of BioMed Central
PubReader format: click here to try


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Gene
    Gene records that cite the current articles. Citations in Gene are added manually by NCBI or imported from outside public resources.
  • GEO Profiles
    GEO Profiles
    Gene Expression Omnibus (GEO) Profiles of molecular abundance data. The current articles are references on the Gene record associated with the GEO profile.
  • HomoloGene
    HomoloGene clusters of homologous genes and sequences that cite the current articles. These are references on the Gene and sequence records in the HomoloGene entry.
  • MedGen
    Related information in MedGen
  • Protein
    Protein translation features of primary database (GenBank) nucleotide records reported in the current articles as well as Reference Sequences (RefSeqs) that include the articles as references.
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...